Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib vs Bevacizumab in First-Line Advanced NSCLC
NCT00600821Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of axitinib in non-small cell lung carcinoma (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression Free Survival up to 2.75 years. Started Apr 2008; status: completed.
02
Drugs
axitinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00600821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600821.